Pharmaceutical Technology-04-02-2018

Pharmaceutical Technology

Pharma 4.0

April 02, 2018

Cover Story

42

4

Pharma 4.0 envisions highly efficient automated processes, which could be continuous, batch, or a hybrid of these, driven by an integrated manufacturing control strategy.

When One Therapy No Longer Fits All

April 02, 2018

From the Editor

42

4

New therapies and tighter budgets challenge bio/pharma to think outside the industry.

Cloud-Connected Platform for Smart Lab Instruments

April 02, 2018

Product Spotlight

42

4

Gilson has added Gilson Connect, a cloud-connected platform that powers a product line of Bluetooth-enabled, smart liquid-handling devices that enable scientists to achieve verifiable science.

Additional Certifications for Touchscreen Panels

April 02, 2018

Product Spotlight

42

4

Ross Systems and Controls (SysCon) touchscreen purged panels have been certified under the standards of Underwriters Laboratories’ (UL)-698A Code and the National Fire Protection Association’s (NFPA)-496 Code.

Automated Benchtop Pipette

April 02, 2018

Product Spotlight

42

4

The Concentrating Pipette Select from InnovaPrep is a small automated benchtop instrument that can concentrate contaminates from large volumes of liquids for improved detection.

CoAs Help Secure the Supply Chain

April 02, 2018

Ask the Expert

42

4

Certificates of analysis can be used to monitor the reliability of products and their suppliers, says Susan Schniepp, distinguished fellow at Regulatory Compliance Associates.

Modern Manufacturing Key to More Effective Vaccines

April 02, 2018

Regulatory Watch

42

4

Accelerated development of new preventives raises challenges for efficient CMC evaluation and production.

ICH Q12 Guidelines Spark Controversies

April 02, 2018

Regulatory Watch

42

4

The flexibility and incompatibility of ICH Q12 guidelines with current EU legislations raise complications.

Future Therapies Using Implanted Engineered Cells as Protein Factories

April 02, 2018

Features

42

4

Researchers at MIT have discovered a new set of compounds that do not elicit a foreign body response when implanted. These biomaterials permit the development of a new category of treatment with the ability to deliver therapeutics either at a constant rate or under programmable conditions by using implantable cells as protein factories.

Pharmaceutical Technology, April 2018 Issue (PDF)

April 02, 2018

Issue PDF

42

4

Click the title above to open the Pharmaceutical Technology April 2018 issue in an interactive PDF format.